The Nicholas Bodor Professor in Drug Discovery
University of Florida, Florida
Dr. Chenglong Li's scholarly interests range from organic chemistry, biochemistry, medicinal chemistry, chemical biology to physical chemistry, computational chemistry, molecular biophysics and pharmacology. His research focuses on molecular recognition, with a strong application to structure-based computer-aided drug design. He combines molecular simulation, artificial intelligence, synthetic chemistry, X-ray protein crystallography, cryo-EM (electron microscopy), thermodynamic measurements, cellular techniques and (in collaboration) in vivo animal models to explore molecular interactions, especially protein-ligand interactions at molecular, cellular and organismal levels. His current working projects include both computational method development and drug design applications, for example: 1) pioneering development of a novel Multiple Ligand Simultaneous Docking (MLSD) strategy, with great potential for Fragment-Based Drug Design (FBDD); 2) development of AI-based deep learning models for molecular design (Elion platform); 3) design and discovery of drugs targeting the cytokine IL-6/STAT3 autoimmune, inflammatory and oncogenic pathway for targeted therapy; 4) design and discovery of drugs targeting epigenetic histone arginine methylation enzymes, especially PRMT5 with both active site and protein-protein interface inhibition; 5) design and discovery of drugs targeting specific nAChR and GPCR subtypes for drug addiction and neurodegenerative diseases; 6) design and discovery of “chemical chaperone” drugs targeting deltaF508 NBD1 misfolding intermediates for potential cystic fibrosis therapy; 7) design and discovery of drugs targeting the YAP/TEAD transcriptional machinery in the Hippo signaling pathway, etc. His current h-index (Google Scholar) is 63.
Disclosure information not submitted.
Sunday, July 21, 2024
1:00 PM – 2:00 PM East Coast USA Time
.png)